08 Apr 2017
2017 MAP Conference | Rationale for Triple Antibiotic Therapy for MAP
Dr. Kalfus is a Medical Director at RedHill Biopharma, which is currently conducting a Phase III FDA trial of a specific combination of antibiotics in Crohn’s disease patients. In his presentation, Dr. Kalfus gives the reason behind triple therapy for MAP and how the three antibiotics were selected. He also talks about how the currently available Crohn’s therapies have some anti-MAP activity. MAP diagnostics, the Selby study and the ongoing RedHill study are also discussed.
Dr. Greenstein is a researcher in the Laboratory of Molecular Surgical Research at the VA Medical Center in Bronx, NY. He presents his research explaining why he believes that the primary action of current Crohn’s disease therapies is really Anti-MAP, and hypothesizes that Crohn’s disease may be the tip of the MAP iceberg. The antimycobacterial effect of Vitamin D is also discussed.
Dr. Chamberlin is a gastroenterologist at the San Antonio Military Medical Center in Texas. In his second presentation, he outlines why he believes that Crohn’s disease is both a disease of immune deficiency and also an infectious disease. The immune system is reviewed, differences in the innate and adaptive immune system are discussed, and genetic mutations which allow MAP to take advantage of certain immune pathways are detailed. Compounds which may stimulate autophagy like turmeric and Vitamin D are discussed. A Q&A session follows the presentation.